Goldman Sachs
RIGL icon

Goldman Sachs’s Rigel Pharmaceuticals RIGL Stock Holding History

Goldman Sachs’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,660
Closed -$133K – 6893
2013
Q4 		$133K Sell
4,660
-16,970
-78% -$498K ﹤0.01% 6164
2013
Q3 		$774K Buy
+21,630
New +$789K ﹤0.01% 4798

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's RIGL Position: Q2 2026 in Review

Goldman Sachs reduced its Rigel Pharmaceuticals (RIGL) stake by 48% in Q2 2026, selling an estimated $6.55M and leaving 226,780 shares worth $8.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

Goldman Sachs first reported a position in RIGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $28.8M in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Goldman Sachs held 226,780 shares of Rigel Pharmaceuticals worth $8.87M as of Q2 2026.
  • Goldman Sachs sold 212,321 Rigel Pharmaceuticals shares in Q2 2026, an estimated $6.55M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3350 holding.
  • Goldman Sachs first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Rigel Pharmaceuticals position peaked at $28.8M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.